Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies

@article{Tousi2017DiagnosisAM,
  title={Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies},
  author={B. Tousi},
  journal={Current Treatment Options in Neurology},
  year={2017},
  volume={19},
  pages={1-19}
}
  • B. Tousi
  • Published 2017
  • Medicine
  • Current Treatment Options in Neurology
Opinion statementProper diagnosis of dementia with Lewy bodies (DLB) in clinical practice remains suboptimal as many cases are misdiagnosed, usually as Alzheimer disease (AD) or Parkinson’s disease (PD) and, in rare cases, psychosis. Therefore, it is important for patients with dementia to be thoroughly evaluated by a specialist who is familiar with current diagnostic tests and treatment options. New diagnostic criteria from the Dementia with Lewy Bodies Consortium have been developed to… Expand
Advances in the pharmacotherapeutic management of dementia with Lewy bodies
TLDR
An overview of the current pharmacotherapy in DLB is provided and potential new drugs are in ongoing clinical trials and it is likely that novel drug targets for the development of better and more effective symptomatic products and disease-modifying therapies are identified. Expand
Clinical drug development for dementia with Lewy bodies: past and present
TLDR
An overview of the DLB drug development landscape and the current treatment strategies is provided and new biomarker strategies are necessary to improve diagnostic capabilities and trial designs, and novel drug targets should be identified to develop DLB specific disease-modifying therapies. Expand
Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism
TLDR
The authors briefly review the DLB drug development pipeline, providing a summary of the current pharmacological intervention studies, and focus on the anticonvulsant zonisamide, a benzisoxazole derivative with a sulfonamide group and look at its value for treating parkinsonism in DLB. Expand
A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies.
TLDR
This study used real-world longitudinal data to create a clinically relevant DLB disease progression model and reduced the rate of disease progression resulted in meaningful benefits with potentially significant public health implications. Expand
The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data
TLDR
Zonisamide significantly improved the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) without affecting the Mini-Mental State Examination (MMSE) or Neuropsychiatry Inventory-10 (NPI-10) scores at week 12. Expand
Lewy Body Dementia: A Review
TLDR
Lewy Body Dementia is a frequent and complex neurodegenerative pathology, shorter in duration than Alzheimer’s disease, although there are few double-blind clinical studies on drug therapies, the place of anticholinesterase inhibitors, L-dopa and new antipsychotics is slowly emerging. Expand
Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update
TLDR
The clinical characteristics, diagnosis, and possible mechanisms of RBD in neurogenerative diseases, including Alzheimer's disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), etc. are updated. Expand
Metabolic Network Topology of Alzheimer’s Disease and Dementia with Lewy Bodies Generated Using Fluorodeoxyglucose Positron Emission Tomography
TLDR
The present findings indicate that metabolic connectivity decreased in both AD andDLB, compared with CN, and DLB was characterized restricted but deeper stereotyped network disruption compared with AD. Expand
The Role of Glial Mitochondria in α-Synuclein Toxicity
TLDR
This work reviews the complex relationship between glial mitochondria and α-syn-mediated neurodegeneration, which may provide novel insights into the roles of glial cells in α- Synucleinopathy-associated Neurodegenerative diseases. Expand
Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies
TLDR
This cross‐sectional study addresses whether depressive symptoms are specifically associated with subjective sleep quality and daytime sleepiness in DLB, and by examining other contributory factors. Expand
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
Diagnosis and management of dementia with Lewy bodies
The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use forExpand
Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia
TLDR
DLB and PDD are important and common dementia syndromes that overlap in their clinical features, neuropathology, and management, believed to exist on a spectrum of Lewy body disease, and some controversy persists in their differentiation. Expand
Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles
TLDR
The results of the present study show that the pattern of cognitive dysfunction, in terms of attention, episodic memory, and executive functions, differ between patients with DLB and patients with AD and PDD. Expand
Utility of Montreal Cognitive Assessment in Differentiating Dementia With Lewy Bodies From Alzheimer’s Dementia
TLDR
It is found that patients with DLB had statistically significant lower performance in clock drawing (visuospatial and executive function) and higher performance in delayed recall (memory) subscores compared to patients with AD, which should raise suspicion for a DLB diagnosis at initial evaluation of patients with dementia. Expand
Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment.
TLDR
A careful and systematic evaluation of BPSD is mandatory for carefully characterizing disease-related features and for developing new therapeutic approaches to improve the allocation of health resources for dementia and to a better management of the disease. Expand
Effectiveness of ramelteon for treatment of visual hallucinations in dementia with Lewy bodies: a report of 4 cases.
TLDR
4 patients with DLB treated with RMT showed mild to moderate cognitive impairment and more than 2 core features including VHs, thereby meeting the diagnostic criteria of probable DLB, supporting the diagnostic validity of DLB. Expand
The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings.
TLDR
It is concluded that the differential diagnosis of LB dementia should be considered in patients satisfying NINCDS-ADRDA criteria for Alzheimer-type dementia who show marked Parkinsonian features and a frontal accentuation of cerebral atrophy. Expand
A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease
TLDR
Neither in the total sample nor in AD or DLB was caregiver-rated anxiety significantly associated with cognitive decline or dementia severity over a 4-year period, but in patients with DLB, self-reported anxiety was associated with a slower cognitive decline than in Patients with AD. Expand
Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia
TLDR
Clinical features and neuropsychological deficiencies of DLB and PD and PD (attentional, visuoperceptive, and visuoconstructive deficits) compared to AD and PD can contribute to accurate identification of these entities and to the understanding of the neuropathological and neurochemical substrate underlying these diseases. Expand
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.
TLDR
Diffuse or transitional Lewy body disease is the primary pathologic substrate for dementia developing later in Parkinson disease and seemed to account for end-stage, levodopa refractory parkinsonism, suggesting common origins or one triggering the other. Expand
...
1
2
3
4
5
...